Develops ARCUS-based gene-editing therapies for genetic and infectious diseases, including chronic hepatitis B and Duchenne muscular dystrophy.
10-K for FY2025, filed Mar 12, 2026We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in…View ↗
We are dedicated to improving life. Our goal is to broadly translate the potential of genome editing into permanent genetic solutions for…View ↗
PBGENE-HBV (Viral Elimination). PBGENE-HBV is our wholly owned in vivo gene editing program under investigation in a global first-in-human…View ↗
PBGENE-DMD (Excision). PBGENE-DMD is our development program for the treatment of Duchenne muscular dystrophy, or DMD. DMD is a genetic…View ↗
Most revenue comes from collaboration and license agreements. Partners pay upfront and option fees, fund research and development, and may make milestone payments; the company may also earn royalties when licensed products are sold.
10-K for FY2025, filed Mar 12, 2026The Company’s revenues are generated primarily through collaborative research, license, development and commercialization agreements.View ↗
Collaborative Arrangements – The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover…View ↗
Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the…View ↗
$34.3M
10-K for FY2025, filed Mar 12, 2026
$34.3M ↗
Biotechnology and pharmaceutical companies partner with Precision to develop, manufacture, or commercialize product candidates and license its technology.
10-K for FY2025, filed Mar 12, 2026In February 2024, we announced that we had granted Caribou Biosciences, Inc. (“Caribou”), a leading CRISPR genome-editing cell therapy…View ↗
On January 7, 2024, we entered into a license agreement (the “TG License Agreement”) with TG Cell Therapy, Inc. (“TG Subsidiary”) and its…View ↗
On August 15, 2023, we entered into an asset purchase agreement (the “Imugene Purchase Agreement”) with Imugene Limited (“Imugene…View ↗
Novartis Pharma AGView ↗
In August 2021, we and iECURE entered into a development and license agreement (the “iECURE DLA”), pursuant to which we are eligible to…View ↗
Collaborative Arrangements – The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover…View ↗
No. It lost $45.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$7.6MView ↗
8-K, filed Nov 6, 2026
Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsView ↗
8-K, filed Nov 5, 2026
Phase 1 ELIMINATE-B study successful, PBGENE-HBV program advancing to Phase 2 PBGENE-HBV achieves target profile at 0.4 mg/kg dose…View ↗
Shrinking. Revenue fell 70% in 4 years, from $115.5M in FY2021 to $34.3M in FY2025, about 26% a year.
Focus on in vivo therapies
The latest report centers on in vivo therapies for genetic and infectious diseases. The older report also described development of ex vivo CAR T immunotherapies for cancer and a strategy to build integrated research, development, manufacturing, and commercial capabilities.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 12, 2026
Loading...